Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Therapy Area topics
Cardiovascular
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Diabetes
EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
Akero’s imperfect Harmony
An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?
Digital Health
ESC 2022 – Preventicus gets halfway there
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Various
Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.